Enter your email address below and subscribe to our newsletter

Patient Education

Share your love

Gr8 Eye Movement Reveals Caregiver Misconceptions

The Gr8 Eye Movement, an awareness campaign led by Prevent Blindness and Regeneron, is focusing on the needs of caregivers for older adults at risk of serious retinal conditions. As the campaign progresses this fall, it continues its mission to…

Nidek’s Mirante Scanning Laser Ophthalmoscope Now in the U.S.

Nidek has launched its Mirante Scanning Laser Ophthalmoscope (SLO) in the United States. The Mirante introduces a multimodal fundus-imaging platform, seamlessly integrating high-definition Scanning Laser Ophthalmoscope (SLO) and optical coherence tomography (OCT) with ultra-wide field imaging capabilities. This platform captures…

Alcon to Unveil Updated MARLO App at SECO 2024

Alcon announced significant updates to its MARLO App, set to be unveiled at the SECO International meeting in Atlanta. This advanced version of the app, featuring new functionalities, aims to further elevate the patient experience. Patients can now conveniently access…

Shamir Launches Spark 4W Eye Measurement Tech

Shamir has launched the Spark 4W, a digital electro-optic measurement system set to revolutionize eye care practices. Leveraging 3D stereo vision technology and artificial intelligence (AI), the Spark 4W aims to streamline and enhance the process of obtaining precise pupillary…

Vision Loss in Seniors Increases Mental Health Risks

In a study published on February 22 in JAMA Ophthalmology, researchers have unveiled a troubling link between vision impairment in adults aged 65 and over and a host of psychosocial issues, including depression, anxiety, and social isolation. The study, led…

Promising Drug for Preventing Diabetic Eye and Kidney Disease

New research led by the University of Bristol has identified a promising type of inhibitor drug that could potentially prevent microvascular diabetic complications, including diabetic eye and kidney disease. The study, published in Cardiovascular Diabetology, focuses on protecting the glycocalyx,…

Aviceda’ Kicks off Phase II/III SIGLEC Trial for AMD

Aviceda Therapeutics has initiated the second part of its Phase II/III SIGLEC trial for AVD-104, an ophthalmic candidate aimed at treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company has dosed the first subject in this phase,…

Stay informed and not overwhelmed, subscribe now!